At a recent meeting of the board that oversees the National Institutes of Health's Clinical Center Research Hospital, chair Jack Leslie opened with cheerful introductions and gregarious chatter—then diverted from the agenda of the regularly scheduled meeting. He spent the next six minutes delivering a pointed rebuke of Health Secretary Robert F. Kennedy, warning that his anti-vaccine activities could tarnish the venerable hospital, often called the "house of hope" for patients with rare conditions or those who have exhausted all other options.

Leslie took issue with a recent stunt Kennedy had pulled at the hospital, which involved making a surprise appearance for a ribbon-cutting ceremony to open his signature vaccine injury clinic. The ceremony included a panel with people claiming to have been injured by vaccines. They sat behind placards reading "vaccine injured" and spoke with Kennedy and other high-ranking Trump administration officials.

Leslie prefaced his comments by noting that some might prefer he not speak out against Kennedy's efforts. "But I think that that would be a failing as an advisory board if we were silent," he said. Leslie also noted that he has no concerns about studying potential injuries from vaccines. "Serious reactions are rare, but real," he said, and people who believe they've been injured should "be taken seriously."

Read full article

Comments

Personalized mRNA vaccines against melanoma—the deadliest form of skin cancer—reduced the risk of death or recurrence by 42 percent compared to standard treatment in a late-stage trial, pharmaceutical partners Merck and Moderna announced Thursday.

The results are a significant advance in melanoma treatment; Merck and Moderna are already engaging with regulatory authorities to get the vaccine approved. More broadly, the vaccine's success bolsters hope that mRNA vaccines and individualized cancer-targeting medicines offer a new paradigm for cancer therapies.

"From the beginning, we believed mRNA technology could make it possible to develop cancer treatments uniquely matched to each patient’s tumor," Moderna CEO Stéphane Bancel said in a statement. The trial results "mark a defining moment for that vision and show what’s possible when we rethink how medicines are made." They also "reinforce our conviction that mRNA has the potential to fundamentally change how we treat cancer," he said.

Read full article

Comments